Alpha Tau Medical Overview
Alpha Tau Medical (DRTS) has a ROE of -210.13%, below the sector sector average of -6.13%.
Get informed when a big investor buys or sells
+ Follow-210.13%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for DRTS is -210.13%. That is below the sector sector average of -6.13%. Investors often review this figure alongside Alpha Tau Medical's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, DRTS currently prints -210.13% for ROE, while the sector average sits near -6.13%. That is roughly 3328.9% below the sector mean. Large gaps often invite a closer look at Alpha Tau Medical's growth, margins, and balance sheet.
Return on Equity shows how effectively Alpha Tau Medical converts resources into returns. At -210.13%, DRTS may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting DRTS's ROE (-210.13%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
